{"id":"colistin-and-meropenem","safety":{"commonSideEffects":["Nephrotoxicity","Neurotoxicity","Diarrhea","Nausea","Injection site reactions"],"contraindications":["Hypersensitivity to colistin, polymyxins, meropenem, or carbapenems"]},"_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Bacterial cell wall and cell membrane","explanation":"Colistin is a polymyxin antibiotic that disrupts the outer membrane of Gram-negative bacteria by binding to lipopolysaccharides. Meropenem is a carbapenem that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. The combination provides synergistic activity against multidrug-resistant Gram-negative pathogens.","oneSentence":"Combines colistin's disruption of bacterial cell membranes with meropenem's inhibition of bacterial cell wall synthesis."},"_scrapedAt":"2026-03-28T01:06:39.224Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122667,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"ceftazidime-avibactam","brand":"Avycaz","company":"Pfizer","rationale":"Beta-lactam/beta-lactamase inhibitor for resistant Gram-negative infections"},{"name":"meropenem-vaborbactam","brand":"Vabomere","company":"Melinta Therapeutics","rationale":"Carbapenem combination for carbapenem-resistant Enterobacteriaceae"},{"name":"cefiderocol","brand":"Fetroja","company":"Shionogi","rationale":"Siderophore cephalosporin for multidrug-resistant Gram-negative bacteria"}],"description":"Colistin and meropenem is a combination antibiotic therapy being investigated by the University of Michigan in Phase 3 trials. This regimen combines a polymyxin antibiotic with a carbapenem to treat serious multidrug-resistant Gram-negative bacterial infections where treatment options are limited.","indications":{"approved":[{"status":"investigational","condition":"Multidrug-resistant Gram-negative bacterial infections","patientPopulation":"Adult patients with limited treatment options"}]},"trialDetails":[{"nctId":"NCT06087536","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex","status":"RECRUITING","sponsor":"Omnix Medical Ltd","startDate":"2026-03","conditions":"Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia","enrollment":54},{"nctId":"NCT07326540","phase":"PHASE3","title":"Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","status":"NOT_YET_RECRUITING","sponsor":"BioVersys SAS","startDate":"2026-03-20","conditions":"Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP), Colistin Resistanrt ABC","enrollment":248},{"nctId":"NCT05922124","phase":"PHASE4","title":"Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2024-09-01","conditions":"Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia, Acinetobacter Pneumonia","enrollment":734},{"nctId":"NCT07089186","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-04-12","conditions":"Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI)","enrollment":80},{"nctId":"NCT07004049","phase":"PHASE4","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-04-21","conditions":"Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia","enrollment":600},{"nctId":"NCT06051513","phase":"NA","title":"Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection","status":"RECRUITING","sponsor":"Southeast University, China","startDate":"2023-11-27","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":404},{"nctId":"NCT03329092","phase":"PHASE3","title":"A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-04-05","conditions":"Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia","enrollment":422},{"nctId":"NCT06419296","phase":"","title":"Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.","status":"COMPLETED","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2024-06-01","conditions":"Bacteremia","enrollment":265},{"nctId":"NCT04882085","phase":"PHASE4","title":"Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-26","conditions":"Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia","enrollment":60},{"nctId":"NCT06198764","phase":"PHASE3","title":"A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-07-06","conditions":"Mental Health Issue","enrollment":80},{"nctId":"NCT05862402","phase":"PHASE4","title":"Dose Optimization by Pharmacokinetic/Pharmacodynamic of Antibiotics to Improve Clinical Outcome of Carbapenem Resistant Klebsiella Pneumoniae Bloodstream Infections in Critically Ill Patients at Phramongkutklao Hospital","status":"UNKNOWN","sponsor":"Phramongkutklao College of Medicine and Hospital","startDate":"2023-05-07","conditions":"Carbapenem Resistant Klebsiella Pneumoniae","enrollment":76},{"nctId":"NCT05850871","phase":"NA","title":"Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-01-06","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":427},{"nctId":"NCT01597973","phase":"PHASE3","title":"Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2012-10-06","conditions":"Pneumonia, Blood Stream Infection","enrollment":467},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04764058","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Colistin Based Antibiotic Therapy","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2017-09-01","conditions":"Septicemia, Bacterial Infections","enrollment":60},{"nctId":"NCT04489459","phase":"PHASE4","title":"Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae","status":"UNKNOWN","sponsor":"Al-Azhar University","startDate":"2019-09-21","conditions":"Treatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella Pneumoniae","enrollment":60},{"nctId":"NCT02894684","phase":"PHASE4","title":"Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis","status":"COMPLETED","sponsor":"Liverpool Heart and Chest Hospital NHS Foundation Trust","startDate":"2017-01","conditions":"Cystic Fibrosis, Infection, Pseudomonas","enrollment":16},{"nctId":"NCT03409679","phase":"PHASE3","title":"Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa","status":"TERMINATED","sponsor":"Polyphor Ltd.","startDate":"2018-03-23","conditions":"Pneumonia","enrollment":41},{"nctId":"NCT01970371","phase":"PHASE3","title":"A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)","status":"COMPLETED","sponsor":"Achaogen, Inc.","startDate":"2014-09-16","conditions":"Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE","enrollment":69},{"nctId":"NCT03622450","phase":"PHASE2, PHASE3","title":"The Effect of Colistin Inhalation on Ventilator Associated Pneumonia","status":"COMPLETED","sponsor":"Nourhan Hassan Osama Thuraya Mohamed","startDate":"2016-01-02","conditions":"Ventilator Associated Pneumonia","enrollment":40},{"nctId":"NCT01732250","phase":"PHASE4","title":"Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem","status":"COMPLETED","sponsor":"Mical Paul","startDate":"2013-03","conditions":"Gram-Negative Bacterial Infections","enrollment":406},{"nctId":"NCT01292031","phase":"PHASE3","title":"Trial of Colistin Versus Meropenem in Ventilator-associated Pneumonia (VAP) (CR-GNB)","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2012-05","conditions":"Ventilator-associated Bacterial Pneumonia","enrollment":232}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Colistimethate","Meropenem"],"phase":"phase_3","status":"active","brandName":"colistin and meropenem","genericName":"colistin and meropenem","companyName":"University of Michigan","companyId":"university-of-michigan","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}